Brief: Cizzle Biotechnology Says Monoclonal Antibody To CIZ1B Now In Assay Optimisation

Cizzle Biotechnology Holdings

05/07/2022 07:32

July 5 (Reuters) - Cizzle Biotechnology Holdings PLC
 CIZ.L :
    * CIZZLE BIOTECHNOLOGY  - UPDATE ON DEVELOPMENT OF
PROPRIETARY
ANTIBODIES
    * CIZZLE BIOTECHNOLOGY-  MONOCLONAL ANTIBODY ("MAB") TO
CIZ1B NOW
IN ASSAY OPTIMISATION; MAB REPORTER PROTEIN DEVELOPED, READY FOR
TEST DEVELOPMENT
    * CIZZLE BIOTECHNOLOGY-  MAB SUPPLIER AGREEMENTS EXTENDED TO
INCREASE USE CASE DIVERSITY; WORK INITIATED TO EXTEND USE CASE
TO BREAST CANCER

Source text for Eikon:  ID:nRSE2826Ra 
Further company coverage:  CIZ.L 

 ((Reuters.Briefs@thomsonreuters.com;))